Tumstatin fusion protein - Ocugen

Drug Profile

Tumstatin fusion protein - Ocugen

Alternative Names: OCU 200; Tumstatin-Transferrin

Latest Information Update: 16 May 2017

Price : $50

At a glance

  • Originator University of Colorado at Anschutz Medical Campus
  • Developer Ocugen
  • Class Recombinant fusion proteins
  • Mechanism of Action Angiogenesis inhibitors; Integrin alphaVbeta3 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Wet age-related macular degeneration

Most Recent Events

  • 08 May 2017 Ocugen has patent protection for OCU 200 in Japan
  • 08 May 2017 Ocugen receives patent allowance for OCU 200 in European Union
  • 22 Mar 2016 Ocugen has patent protection for OCU 200 in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top